A study by Conley et al. demonstrated that the administration of antiangiogenic agents such as the VEGF receptor TKI sunitinib and the anti-VEGF antibody bevacizumab increases the cancer stem cells population in breast cancer xenografts because of the generation of tumor hypoxia [30]. Here, VEGFA is linked to breast cancer.